- Home
- IMNM vs SBSI Comparison
IMNM vs SBSI Comparison
Compare IMNM & SBSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- SBSI
- Stock Information
- Founded
- IMNM 2006
- SBSI 1960
- Country
- IMNM United States
- SBSI United States
- Employees
- IMNM N/A
- SBSI N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- SBSI Major Banks
- Sector
- IMNM Health Care
- SBSI Finance
- Exchange
- IMNM Nasdaq
- SBSI Nasdaq
- Market Cap
- IMNM 747.7M
- SBSI N/A
- IPO Year
- IMNM 2020
- SBSI N/A
- Fundamental
- Price
- IMNM $12.23
- SBSI $33.14
- Analyst Decision
- IMNM Strong Buy
- SBSI
- Analyst Count
- IMNM 4
- SBSI 0
- Target Price
- IMNM $28.75
- SBSI N/A
- AVG Volume (30 Days)
- IMNM 883.2K
- SBSI 112.7K
- Earning Date
- IMNM 11-07-2024
- SBSI 10-24-2024
- Dividend Yield
- IMNM N/A
- SBSI 4.34%
- EPS Growth
- IMNM N/A
- SBSI N/A
- EPS
- IMNM N/A
- SBSI 2.69
- Revenue
- IMNM $10,784,000.00
- SBSI $240,491,000.00
- Revenue This Year
- IMNM N/A
- SBSI N/A
- Revenue Next Year
- IMNM N/A
- SBSI $5.06
- P/E Ratio
- IMNM N/A
- SBSI $12.30
- Revenue Growth
- IMNM 62.73
- SBSI N/A
- 52 Week Low
- IMNM $6.93
- SBSI $25.30
- 52 Week High
- IMNM $30.96
- SBSI $36.10
- Technical
- Relative Strength Index (RSI)
- IMNM 36.79
- SBSI 53.16
- Support Level
- IMNM $12.24
- SBSI $31.70
- Resistance Level
- IMNM $13.40
- SBSI $32.73
- Average True Range (ATR)
- IMNM 0.77
- SBSI 0.73
- MACD
- IMNM -0.24
- SBSI -0.06
- Stochastic Oscillator
- IMNM 14.41
- SBSI 65.22
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.